Vor Biopharma (VOR) 10% owners sell $2.46 million in stock

Following these transactions, Reprogrammed Interchange LLC directly holds 34,213,292 shares of Vor Biopharma Inc. common stock. Reid Hoffman may be deemed a beneficial owner of these shares due to his shared control and indirect pecuniary interest in Reprogrammed Interchange LLC, although he disclaims beneficial ownership except to the extent of his pecuniary interest. Get deeper insights into insider trading patterns and access 12 additional key ProTips for VOR through InvestingPro’s comprehensive research reports. Get deeper insights into insider trading patterns and access 12 additional key ProTips for VOR through InvestingPro’s comprehensive research reports.

Following these transactions, Reprogrammed Interchange LLC directly holds 34,213,292 shares of Vor Biopharma Inc. common stock. Reid Hoffman may be deemed a beneficial owner of these shares due to his shared control and indirect pecuniary interest in Reprogrammed Interchange LLC, although he disclaims beneficial ownership except to the extent of his pecuniary interest. Get deeper insights into insider trading patterns and access 12 additional key ProTips for VOR through InvestingPro’s comprehensive research reports.

Following these transactions, Reprogrammed Interchange LLC directly holds 34,213,292 shares of Vor Biopharma Inc. common stock. Reid Hoffman may be deemed a beneficial owner of these shares due to his shared control and indirect pecuniary interest in Reprogrammed Interchange LLC, although he disclaims beneficial ownership except to the extent of his pecuniary interest.

In other recent news, Vor Biopharma Inc. announced that its shareholders have approved changes to the company’s 2021 Equity Incentive Plan, increasing the number of shares reserved for issuance by 25 million. Additionally, the plan’s annual automatic increase in the share reserve has been reduced from 5% to 4% of outstanding shares each year through 2035. In collaboration news, Vor Biopharma’s partner, RemeGen Co., Ltd, successfully achieved the primary endpoint in a Phase 3 clinical trial for telitacicept in adults with IgA nephropathy in China. The study demonstrated a significant 55% reduction in the 24-hour urine protein-to-creatinine ratio at 39 weeks compared to placebo. The company also announced changes to its board of directors, with the resignation of Joshua Resnick, M.D., Matthew Patterson, and David Lubner. Vor Biopharma has appointed Alexander Cumbo and Michel Detheux, Ph.D., to its board, effective July 16, 2025. These developments reflect ongoing strategic and operational changes within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.